ONCT vs. VTGN, DMAC, COYA, ALLK, TLSA, AFMD, LFVN, IFRX, ASRT, and VSTM
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Coya Therapeutics (COYA), Allakos (ALLK), Tiziana Life Sciences (TLSA), Affimed (AFMD), LifeVantage (LFVN), InflaRx (IFRX), Assertio (ASRT), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics (NASDAQ:ONCT) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
Oncternal Therapeutics has higher earnings, but lower revenue than Vistagen Therapeutics.
Vistagen Therapeutics received 251 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 31.58% of users gave Oncternal Therapeutics an outperform vote.
In the previous week, Vistagen Therapeutics had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 2 mentions for Vistagen Therapeutics and 1 mentions for Oncternal Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.77 beat Oncternal Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Oncternal Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Oncternal Therapeutics presently has a consensus price target of $28.33, suggesting a potential upside of 245.53%. Vistagen Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 401.32%. Given Vistagen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vistagen Therapeutics is more favorable than Oncternal Therapeutics.
Vistagen Therapeutics has a net margin of -3,073.51% compared to Oncternal Therapeutics' net margin of -3,160.73%. Vistagen Therapeutics' return on equity of -72.10% beat Oncternal Therapeutics' return on equity.
16.1% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Vistagen Therapeutics beats Oncternal Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
